Kutanöz Mastositoz

Merve ERKOÇa, Göksal KESKİNa
aAnkara Üniversitesi Tıp Fakültesi, İmmünoloji ve Alerji Hastalıkları BD, Ankara, TÜRKİYE

Erkoç M, Keskin G. Kutanöz mastositoz. Çildağ S, editör. İmmünolojik ve Alerjik Deri Hastalıkları. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.25-8.

ÖZET
Mastositoz; bir veya daha fazla organda mast hücrelerinin anormal proliferasyonundan ve infiltrasyonundan kaynaklanan heterojen bir hastalık grubudur. Kutanöz mastositoz (CM) ciltle sınırlı mastositozdur. İzole kutanöz mastositoz baskın olarak çocukları etkilemekle birlikte nadiren de olsa yetişkin popülasyonu etkilemektedir. Kutanöz mastositoz 3 alt gruba ayrılmıştır ve en sık görülen şikayet kaşıntıdır. Kutanöz mastositoz tanısı tipik klinik bulguları olan hastalarda ciltten alınan biyopsiyledir. Tedavide amaç mast hücrelerden salgılanan mediyatörler ile ilişkili semptomların kontrolüdür. Kutanöz mastositoz prognozu hastanın başvuru sırasındaki yaş ile ilişkilidir.

Anahtar Kelimeler: Mastositoz, kutanöz; ürtikerya pigmentoza; mastositoma, deri

Referanslar

  1. Komi DE, Rambasek T, Wöhrl S. Mastocytosis: from a Molecular Point of View. Clin Rev Allergy Immunol. 2018;54(3):397-411. [Crossref]  [PubMed]  [PMC]
  2. Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 2004;114(1):3-11. [Crossref]  [PubMed]
  3. Meni C, Bruneau J, Georgin-Lavialle S, Le Saché de Peufeilhoux L, Damaj G, Hadj-Rabia S, et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015;172:642-51. [Crossref]  [PubMed]
  4. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25(7):519-28. [Crossref]  [PubMed]
  5. Fradet M, Negretto M, Tournier E, et al. Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study. J Eur Acad Dermatol Venereol. J Eur Acad Dermatol Venereol. 2019;33(9):1713-8. [Crossref]  [PubMed]
  6. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-7. [Crossref]  [PubMed]  [PMC]
  7. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. Ann Allergy. 1994;73:197.
  8. Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am. 2000;14:537. [Crossref]  [PubMed]
  9. CAPLAN RM. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol. 1963;87:146. [Crossref]  [PubMed]
  10. Macri A, Cook C. Urticaria Pigmentosa (Cutaneous Mastocytosis). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. 2019 Apr 11.
  11. Van Gysel D, Van Schail R, Oranje A: Mastocytosis. In Textbook Of Pediatric Dermatology (Harper J, Oranje A, and Prose N). 2nd ed. Oxford: Blackwell Scientific; 2006. p.703-17.
  12. Sukesh MS, Dandale A, Dhurat R, Sarkate A, Ghate S. Case Report: Solitary mastocytoma treated successfully with topical tacrolimus. F1000Res. 2014;3:181 [Crossref]  [PubMed]  [PMC]
  13. Lee EH, Kim MR, Kang TW, Kim SC. Diffuse cutaneous mastocytosis with generalized bullae. Ann Dermatol. 2010;22(1):77-80. [Crossref]  [PubMed]  [PMC]
  14. Potier A, Lavigne C, Chappard D, Verret JL, Chevailler A, Nicolie B, et al. Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase. Clin Exp Allergy. 2009;39(5):717- 25. [Crossref]  [PubMed]
  15. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435-53. [Crossref]  [PubMed]
  16. Hinojosa T, Lewis DJ, Vangipuram R, Laraib Safeer BA, Mui UN, Haley C, et al. The efficacy of omalizumab in cutaneous mastocytosis: a case series. Dermatol Ther. 2019;32:e12848. [Crossref]  [PubMed]
  17. Alvarez-Twose I, Vañó-Galván S, SánchezMuñoz L, Morgado JM, Matito A, Torrelo A, et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy. 2012;67(6):813-21. [Crossref]  [PubMed]  [PMC]
  18. Mann C, Sepp N, Simma B. Congenital cutaneous mastocytosis. J Pediatr. 2004;145(1):134. [Crossref]  [PubMed]
  19. Le M, Miedzybrodzki B, Olynych T, Chapdelaine H, Ben‐Shoshan M. Natural history and treatment of cutaneous and systemic mastocytosis. Postgrad Med. 2017;129: 896‐901. [Crossref]  [PubMed]
  20. Czarny J, Lange M, Ługowska-Umer H, Nowicki RJ. Cutaneous mastocytosis treatment: strategies, limitations and perspectives. Postepy Dermatol Alergol. 2018;35(6):541-5. [Crossref]  [PubMed]  [PMC]
  21. Matito A, Blázquez-Goñi C, Morgado JM, Alvarez-Twose I, Mollejo M, Sánchez-Muñoz L, et al. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol. 2013;111(5):425- 6. [Crossref]  [PubMed]
  22. Morren MA, Hoppé A, Renard M, Debiec Rychter M, Uyttebroeck A, Dubreuil P, et al. Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. J Pediatr. 2013;162(1):205-7. [Crossref]  [PubMed]
  23. Vaes M, Benghiat FS, Hermine O. Targeted Treatment Options in Mastocytosis. Front Med (Lausanne). 2017;4:110. [Crossref]  [PubMed]  [PMC]
  24. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3): 804-15. [Crossref]  [PubMed]
  25. Auquit-Auckbur I, Lazar C, Deneuve S, Guillemet C, Cordel N, Blanchard F, et al. Malignant transformation of mastocytoma developed on skin mastocytosis into cutaneous mast cell sarcoma. Am J Surg Pathol. 2012;36(5):779-82. [Crossref]  [PubMed]
  26. Chantorn R, Shwayder T. Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia. Pediatr Dermatol 2012;29:605. [Crossref]  [PubMed]